BSX Q1 2026 Earnings Transcript

Boston Scientific cut full-year 2026 organic revenue guidance to 6.5%-8% from prior expectations after headwinds in EP, WATCHMAN, and Urology, even though Q1 organic revenue rose 9.4% and adjusted EPS of $0.80 matched the high end of guidance. Adjusted gross margin fell 100 bps to 70.5% due to tariffs and POLARx discontinuation charges, and management now expects full-year gross margin to be slightly below 2025. The company authorized an additional $4 billion in buybacks, plans to repurchase about $2 billion in Q2, and still expects the Penumbra deal to close in 2H 2026.

Analysis

The key read-through is not just a 2026 reset, but a probable 2H26/2027 re-acceleration setup getting cheaper. BSX is effectively trading off near-term growth credibility for cleaner product-cycle optics: the mix drag from discontinued products and weaker high-margin procedural call points will pressure gross margin, but that also forces a more disciplined capital allocation regime and a heavier buyback backstop into a softer tape.

The bigger second-order issue is competitive. In EP, the message implies the company is still the leader, but no longer the uncontested default, which usually shows up first in U.S. account-level share before it becomes visible in the top line. That matters because EP is the ecosystem anchor: any share loss there can ripple into mapping, catheters, and adjacent procedural pull-through, while also giving rivals a window to widen installed-base switching costs before next-gen launches arrive.

WATCHMAN looks more like a timing problem than a thesis break, but the market is likely underestimating how long guideline/label/coverage translation takes after strong trial data. The near-term risk is that “concomitant” growth masks continued erosion in stand-alone volumes, so the business can look stable while mix quietly worsens. If hospital workflow constraints persist into summer, this becomes a months-long headwind rather than a one-quarter blip.

Contrarian takeaway: the guidance cut may be too punitive if investors extrapolate 1Q weakness linearly. BSX has multiple 2027 catalysts, significant FCF, and a large buyback program that can offset multiple compression, but the stock likely needs one more quarter of proof that Urology stabilizes and EP share does not keep slipping before rerating is credible.

Key Decisions for Investors

• Long BSX on a 3-6 month horizon if the stock sells off further on guidance reset; risk/reward improves if it trades toward low-20s forward EPS, with buybacks providing downside support and 2027 catalysts as upside optionality.
• Pair trade: long BSX / short SYK over the next 1-2 quarters as a relative value trade on product-cycle execution and margin defense; BSX has more visible near-term noise but better compressed valuation and larger capital returns.
• Buy BSX Jan-2027 calls or call spreads after the next earnings print if management shows Urology stabilization and no further EP share erosion; this is a timing trade on a 12-18 month re-acceleration rather than a near-term momentum trade.
• Avoid chasing PEN into the deal vote; use only as a merger-arb/tight-spread event trade, because upside is capped and any added cash uncertainty can widen the discount quickly.
• For risk-controlled positioning, sell put spreads in BSX around the post-earnings implied vol peak; the stock has recurring fundamental support from FCF and repurchase capacity, but the near-term guide-down limits upside until the market sees a second-half inflection.